BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results

Noble Affirms BioCryst Pharma (BCRX) at 'Buy' Following Q4 Results; Two Oral HAE Programs Moving Forward

February 24, 2016 11:57 AM EST

Noble Financial affirms BioCryst Pharma (Nasdaq: BCRX) with a Buy rating and $8 price target after the company reported... More

BioCryst Pharma (BCRX) Tops Q4 EPS by 1c

February 23, 2016 7:21 AM EST

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

... More